Drug Profile

VAX A1

Alternative Names: GAS carbohydrate conjugate vaccine-Vaxcyte; Streptococcal conjugate vaccine - Vaxcyte; VAX-A1

Latest Information Update: 20 Apr 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Vaxcyte
Class Conjugate vaccines; Protein vaccines; Streptococcal vaccines; Synthetic vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes - Streptococcal infections

Highest Development Phases

Preclinical Streptococcal infections

Most Recent Events

18 Apr 2023 9386481: No updates
28 Feb 2022 Vaxcyte plans to file an IND application to the US FDA in the second half of 2022
29 Mar 2021 Vaxcyte plans to initiate IND-enabling studies in the second half of 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com